Click on the links below to view Sovereign Pharma’s media coverages, press releases, and company brochure.
Publication : LiveMint
Vaccine manufacturers and ancillaries are anticipating a strong demand from the government for Covid-19 vaccines alone after the government
announced its plans to procure ₹35,000 crore worth of jabs, an amount estimated to be enough to vaccinate roughly half of the country’s
population.
Publication : LiveMint
Year : May – 2021
Indian drug vial maker Schott Kaisha is expecting annual vial sales for
COVID-19 shots to more than triple as vaccine production, including by
one of its top customers Serum Institute, increases in response to a
monster second wave of infections.
Publication : The Hindu Bussiness Line
Year : June – 2021
Over the last 15-odd months, the surge in demand for medicines to treat
Covid-19 has been intense and with life-and-death consequences for
patients.But navigating this ebb and flow in demand are a bunch of
rather low-profile companies.
Publication : Business Standard
Year : Oct – 2021
Leading German specialty glass maker SCHOTT Glass India has announced an additional investment of 70 million euros to expand its Gujarat tubing plant that already makes FIOLAX glass used in Covid-19 vaccine packaging in India.
Publication : BioSpectrum India
Year : Dec – 2021
Pharma-packaging firm based in Mumbai, Kaisha Packaging has successfully
provided over 2 billion doses worth of flip-top aluminium seals used for
packaging COVID-19 vaccines.
The seal is used as a closure for injection vials during the vaccination
drive and is as such an essential part of the vaccine package ensuring
tamper-proof delivery.
Publication : Packaging SouthAsia
Year : Dec – 2021
Pharma-packaging firm based in Mumbai, Kaisha Packaging has successfully
provided over 2 billion doses worth of flip-top aluminium seals used for
packaging COVID-19 vaccines.
The seal is used as a closure for injection vials during the vaccination
drive and is as such an essential part of the vaccine package ensuring
tamper-proof delivery.
Publication : Financial Express
Year : Aug – 2020
With several countries joining the race for the Coronavirus vaccine, India has been getting several requests for the supply of ampoules, vials and syringes which play a critical role in administering the vaccine to the population on a mass level
Publication : LiveMint
Year : Sept – 2020
Makers of vials and syringes have started building up capacity in anticipation of a surge in demand if and when a successful covid-19 vaccine is launched in India—a market that could hit $6 billion.
Publication : Business Standard
Year : Dec – 2020
India, the world’s biggest vaccine maker, is getting set for the massive global blitz to contain the coronavirus pandemic with its pharmaceutical industry and partners freeing up capacity and accelerating investments even without firm purchase ordersp>
Publication : The Indian Express
Year : Dec – 2020
With at least two Covid-19 vaccines closer to regulatory approvals and a couple of international candidates set to be manufactured in the country, makers of medical devices are ramping up capacity in anticipation of a potential surge in demand for vials and syringes.
Publication : LiveMint
Year : Dec – 2020
India, the world’s biggest vaccine maker, is getting set for the massive global blitz to contain the coronavirus pandemic with its pharmaceutical industry and partners freeing up capacity and accelerating investments even without firm purchase orders.
Publication : Packaging SouthAsia
Year : Feb – 2019
Vaccine manufacturers and ancillaries are anticipating a strong demand
from the government for Covid-19 vaccines alone after the government
announced its plans to procure ₹35,000 crore worth of jabs, an amount
estimated to be enough to vaccinate roughly half of the country’s
population.
Publication : Bussiness World
Year : sept – 2018
The three-decade old partnership of Kairus Dadachanji and Shapoorji Pallonji Mistry has resulted in yet another milestone in India’s pharmaceutical landscape with the birth of ‘KAISHA LIFESCIENCES’.
With multi-crore investment and a team of skilled pharma specialists committed to developing superior quality generic injectables and any other forms of medicine, KAISHA LIFESCIENCES is a privately-owned company